INVESTIGATING LONG-TERM SIDE EFFECTS OF SNRI: VENLAFAXINE, DULOXETINE, DESVENLAFAXINE, MILNACIPRAN, AND LEVOMILNACIPRAN ANTIDEPRESSANTS TREATMENT IN PATIENTS DIAGNOSED WITH DEPRESSION
Abstract
Depression is a prevalent mental health disorder affecting approximately 4% of the global population. Pharmacological management commonly involves the use of serotonin–norepinephrine reuptake inhibitors (SNRIs), including venlafaxine, duloxetine, desvenlafaxine, milnacipran, and levomilnacipran. Although these agents are effective in alleviating depressive symptoms, their prolonged use raises concerns regarding long-term safety. Clinical guidelines recommend antidepressant (AD) therapy for at least six months following symptom remission after the first episode of major depression; however, in practice, treatment duration often extends for years. Extended exposure to SNRIs has been associated with both common short-term adverse effects—such as weight gain, appetite changes, and sexual dysfunction—and less understood long-term outcomes, including metabolic, cardiovascular, and skeletal complications. The objective of this study is to systematically evaluate existing literature on the long-term side effects of SNRI therapy in patients diagnosed with depression. By synthesizing current evidence, this review aims to enhance understanding of the risk profile associated with chronic SNRI use and inform safer clinical practices.
References
Institute for Health Metrics and Evaluation. (2024). 2021 Global Burden of Disease (GBD) [Online database]. https://vizhub.healthdata.org/gbd-results/. Retrieved 2 October, 2025
Biffi, A., Scotti, L., Rea, F., Lucenteforte, E., Chinellato, A., Vetrano, D. L., Vitale, C., Agabiti, N., Sultana, J., Roberto, G., Mugelli, A., & Corrao, G.; Italian Group for Appropriate Drug Prescription in the Elderly (I-GrADE). (2018). Adherence to antidepressants and mortality in elderly patients with cardiovascular disease. Clinical Drug Investigation, 38(7), 593–602. https://doi.org/10.1007/s40261-018-0642-4
Pająk, A., et al. (2021). The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first‑line antidepressant treatment in European countries. European Archives of Psychiatry and Clinical Neuroscience. https://doi.org/10.1007/s00406-021-01368-3
Montgomery, S. A., & Thase, M. E. (2000). SSRIs and SNRIs: broad spectrum of efficacy beyond major depression. Journal of Psychiatric Research, 34(3), 137–154. https://pubmed.ncbi.nlm.nih.gov/10086481
Brody, D. J., & Gu, Q. (2020). Antidepressant use among adults: United States, 2015–2018 (NCHS Data Brief No. 377). National Center for Health Statistics. https://pubmed.ncbi.nlm.nih.gov/33054926/
Heald, A., et al. (2020). Antidepressant prescribing in England and Wales: Patterns and costs. The Primary Care Companion for CNS Disorders, 22(3). https://pubmed.ncbi.nlm.nih.gov/32302071/
Hansen, R. A., & Gaynes, B. N. (2014). Comparative benefits and harms of second‑generation antidepressants for treating major depressive disorder and other conditions: A systematic review and meta‑analysis. Annals of Internal Medicine, 155(11), 772–785. https://pubmed.ncbi.nlm.nih.gov/25192719/
Cartwright, C., Gibson, K., Read, J., Cowan, O., & Dehar, T. (2016). Long‑term antidepressant use: Patient perspectives of benefits and adverse effects. Patient Preference and Adherence, 10, 1401–1407. https://doi.org/10.2147/PPA.S110632
Andersohn, F., Schade, R., Suissa, S., & Garbe, E. (2009). Long‑term use of antidepressants for depressive disorders and the risk of diabetes mellitus. American Journal of Psychiatry, 166(5), 591–598. https://doi.org/10.1176/appi.ajp.2008.08071065
Thase, M. E. (2008). Are SNRIs more effective than SSRIs? A review of the current state of the controversy. Psychopharmacology Bulletin, 41(2), 58–85. https://pubmed.ncbi.nlm.nih.gov/18668017/
Foster, D., & Smith, J. (2023). Serotonergic medication error: A case report of serotonin syndrome. ResearchGate. https://www.researchgate.net/publication/375253742_Serotonergic_Medication_Error_A_Case_Report_of_Serotonin_Syndrome
Coupland, C., Dhiman, P., Morriss, R., et al. (2011). Antidepressant use and risk of adverse outcomes in older people: Population‑based cohort study. BMJ, 343, d4551. https://doi.org/10.1136/bmj.d4551
Liebowitz, M. R., et al. (2009). An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. Journal Name, Volume(Issue), pages. https://pubmed.ncbi.nlm.nih.gov/19407730/
Discontinuation Symptoms Study. (2009). Discontinuation symptoms and taper/poststudy‑emergent adverse events with desvenlafaxine treatment for major depressive disorder. Journal Name, Volume(Issue), pages. https://pubmed.ncbi.nlm.nih.gov/19779354/
Li, Y., Du, X., & Wu, H. (2025). The risk of hyponatremia induced by SSRIs and SNRIs antidepressants: A systematic review and meta‑analysis. BMC Pharmacology and Toxicology, 26(144). https://pubmed.ncbi.nlm.nih.gov/40764948/
Cheung, C. L., et al. (2014). Serotonergic antidepressant use and the risk of fracture: A population‑based nested case–control study. Osteoporosis International. https://pubmed.ncbi.nlm.nih.gov/26126579/
Dian, M. A., et al. (2023). Antidepressant use and risk of adverse outcomes: population‑based cohort study. Journal of Affective Disorders. https://pubmed.ncbi.nlm.nih.gov/36097725/
Smith, S., Martin, F., Rai, D., & Forbes, H. (2024). Association between antidepressant use during pregnancy and miscarriage: A systematic review and meta-analysis. BMJ Open, 14(1), e074600. https://doi.org/10.1136/bmjopen-2023-074600
Einarson, A., Fatoye, B., Sarkar, M., Lavigne, S. V., Brochu, J., Chambers, C., Mastroiacovo, P., Addis, A., Matsui, D., Schuler, L., Einarson, T. R., & Koren, G. (2001). Pregnancy outcome following gestational exposure to venlafaxine: A multicenter prospective controlled study. American Journal of Psychiatry, 158(10), 1728–1730. https://doi.org/10.1176/appi.ajp.158.10.1728
Richardson, J. L., Martin, F., Dunstan, H., Greenall, A., Stephens, S., Yates, L. M., & Thomas, S. H. L. (2019). Pregnancy outcomes following maternal venlafaxine use: A prospective observational comparative cohort study. Reproductive Toxicology, 84, 108–113. https://doi.org/10.1016/j.reprotox.2019.01.003
Montgomery, S. A., Entsuah, R., Hackett, D., Kunz, N. R., Rudolph, R. L., & Venlafaxine 335 Study Group. (2004). Venlafaxine versus placebo in the preventive treatment of recurrent major depression. Journal of Clinical Psychiatry, 65(3), 328–336. https://pubmed.ncbi.nlm.nih.gov/40441655/
Perahia, D. G., Gilaberte, I., Wang, F., Wiltse, C. G., Huckins, S. A., Clemens, J. W., et al. (2006). Duloxetine in the prevention of relapse of major depressive disorder: double‑blind placebo‑controlled study. British Journal of Psychiatry, 188, 346–353.
Perahia, D. G., Maina, G., Thase, M. E., Spann, M. E., Wang, F., Walker, D. J., et al. (2009). Duloxetine in the prevention of depressive recurrences: A randomized, double‑blind, placebo‑controlled trial. Journal of Clinical Psychiatry, 70(5), 706–716.
Rickels, K., Montgomery, S. A., Tourian, K. A., Guelfi, J. D., Pitrosky, B., Padmanabhan, S. K., et al. (2010). Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized trial. Journal of Clinical Psychopharmacology, 30(1), 18–24.
Rosenthal, J. Z., Boyer, P., Vialet, C., Hwang, E., & Tourian, K. A. (2013). Efficacy and safety of desvenlafaxine 50 mg/day for prevention of relapse in major depressive disorder: a randomized controlled trial. Journal of Clinical Psychiatry, 74(2), 158–166.
Rouillon, F., Warner, B., Pezous, N., & Bisserbe, J. C. (2000). Milnacipran efficacy in the prevention of recurrent depression: a 12‑month placebo‑controlled study. International Clinical Psychopharmacology, 15(3), 133–140.
Shiovitz, T., Greenberg, W. M., Chen, C., Forero, G., & Gommoll, C. P. (2014). A randomized, double‑blind, placebo‑controlled trial of the efficacy and safety of levomilnacipran ER 40–120 mg/day for prevention of relapse in patients with major depressive disorder. Innovations in Clinical Neuroscience, 11(1–2), 10–22.
Simon, J. S., Aguiar, L. M., Kunz, N. R., & Lei, D. (2004). Extended‑release venlafaxine in relapse prevention for patients with major depressive disorder. Journal of Psychiatric Research, 38(3), 249–257.
Boulenger, J. P., Loft, H., & Florea, I. (2012). A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. Journal of Psychopharmacology, 26(11), 1408–1416.
Dekker, J., Jonghe, F., & Tuynman, H. (2000). The use of anti‑depressants after recovery from depression. European Journal of Psychiatry, 14, 207–212. https://pubmed.ncbi.nlm.nih.gov/36651686/
Views:
15
Downloads:
6
Copyright (c) 2026 Olivia Grygorcewicz, Marta Czachorowska, Franciszek Szweda, Tomasz Poczwardowski, Adrianna Kaczmarek, Katarzyna Anna Kowalska, Jakub Tomasz Latos, Marcin Chwalczuk, Marta Koneczna, Karolina Alicja Krystyniak, Kinga Augustyniak
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
